0001479290-24-000074.txt : 20240417
0001479290-24-000074.hdr.sgml : 20240417
20240417163450
ACCESSION NUMBER: 0001479290-24-000074
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240416
FILED AS OF DATE: 20240417
DATE AS OF CHANGE: 20240417
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jordan Erica
CENTRAL INDEX KEY: 0002012846
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36297
FILM NUMBER: 24851565
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Revance Therapeutics, Inc.
CENTRAL INDEX KEY: 0001479290
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770551645
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6157247755
MAIL ADDRESS:
STREET 1: 1222 DEMONBREUN STREET
STREET 2: SUITE 2000
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
wk-form4_1713386078.xml
FORM 4
X0508
4
2024-04-16
0
0001479290
Revance Therapeutics, Inc.
RVNC
0002012846
Jordan Erica
C/O REVANCE THERAPEUTICS, INC.
1222 DEMONBREUN STREET, 20TH FLOOR
NASHVILLE
TN
37203
0
1
0
0
Chief Commercial Officer
0
Common Stock
2024-04-16
4
S
0
2392
3.8028
D
114864
D
Represents the number of shares required to be sold by the Reporting Person, to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") granted on April 3, 2023 which vest in equal installments over a four year period. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the
number of shares sold at each separate price.
/s/ Dwight Moxie, Attorney-in-Fact
2024-04-17